Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
TriPRIL trial: what clinicians have said so far
TriPRIL CAR T Cells in Multiple Myeloma
- NCT05020444 ↗
- Active, not recruiting
- Marcela V. Maus, M.D.,Ph.D.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on TriPRIL (relapsed or refractory multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TriPRIL so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma; Multiple Myeloma in Relapse; Refractory Multiple Myeloma
- Interventions
- TriPRIL CAR T Cells; Cyclophosphamide; Fludarabine
- Arms
- TriPRIL CAR T Cells-Dose Escalation · Experimental
- TriPRIL CAR T Cells-Dose Expansion · Experimental
- Enrollment
- 16
- Primary outcomes
- Incidence of adverse events (AEs)
- Incidence of Dose Limiting Toxicity (DLT)
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Start
- Oct 5, 2021
- Primary completion
- Feb 24, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05020444 · updated Aug 7, 2026